RESEARCH MONOGRAPH · KDC-MN-289

Levothyroxine (T4)

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

87/100

The most-prescribed drug in the US for a reason, but the monotherapy-only orthodoxy is overdue for a rethink

Levothyroxine is the workhorse and it earns the title. T4 is the prohormone form, biologically inactive until the deiodinases convert it to T3 in peripheral tissues, with a half-life of about 7 days that makes once-daily dosing trivially easy and the receptor occupancy curve almost flat. From a pharmacokinetic engineering standpoint it's a near-perfect drug.

The mechanism is textbook. T4 enters cells via MCT8/MCT10 transporters, gets deiodinated to T3 by DIO1 (liver, kidney, primarily systemic T3 supply) and DIO2 (pituitary, brain, brown adipose, primarily local T3 supply), and the T3 then binds TR-alpha and TR-beta in the nucleus. The DIO2 pathway is the interesting one because it's tissue-specific and runs partly outside the systemic T3 pool.

The evidence base is enormous. Levothyroxine has been the standard of care for hypothyroidism for decades, supported by tens of thousands of patient-years of data. The dose titration logic (start low, monitor TSH, adjust by 12.5-25 mcg increments) is well-established and reproducible across most patients.

What's underappreciated is that the T4-monotherapy-is-always-correct orthodoxy has cracks. The DIO2 Thr92Ala polymorphism work suggests a subset of patients have impaired peripheral T4-to-T3 conversion, and the combination therapy literature (T4 plus a small T3 dose) shows meaningful symptom improvement in some patient subgroups even when standard biomarkers look fine on T4 alone. The endocrinology guidelines have been slow to acknowledge this and the literature deserves a clearer reading.

What we like: pharmacokinetic predictability, decades of clinical experience, and the reality that T4 monotherapy works fine for most hypothyroid patients. Cheap, well-characterized, easy to dose.

What we dont love is the dismissive tone the field has historically taken toward the subset of patients who report incomplete symptom resolution on T4 alone. That literature has been firming up in the last 10-15 years.

Sourcing is excellent. Levothyroxine sodium is pharma-scale, USP-monographed, and stable. The bioequivalence concerns between generic formulations are real but well-characterized, and research-grade material is straightforward.

Evidence: 95
Mechanism: 92
Reliability: 90
Safety: 82
Sourcing: 90
Value: 85
Signal: 72
Staying power: 88

Plain-language summary Intrigue 55 / 100

Levothyroxine (Synthroid, Levoxyl, Tirosint) is synthetic T4 and the most-prescribed drug in the United States, with over 100 million annual prescriptions. It is a prohormone: the body converts it to active T3 in tissues via deiodinase enzymes. The slow conversion gives smooth plasma levels over its 7-day half-life, in contrast to the short, peaky profile of direct T3. Approved across multiple brands since 1955 for hypothyroidism, including primary, secondary, and post-thyroidectomy cases, and for thyroid cancer to suppress TSH. Bioequivalence between brands has been a long-running political issue (small dose differences can matter in narrow-therapeutic-index patients). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Thyroid prohormone (T4)

Synthetic thyroxine; the standard hypothyroidism treatment and the most prescribed drug in the United States.

Abstract

Levothyroxine (3,3',5,5'-tetraiodo-L-thyronine, T4; CAS 51-48-9; molecular formula C15H11I4NO4; molecular weight 776.87) is synthetic L-thyroxine, the principal thyroid hormone produced by the thyroid gland. Approved by the FDA from 1955 (multiple manufacturers; brands include Synthroid, Levoxyl, Tirosint). The compound is a prohormone: T4 is converted by deiodinases (D1, D2) to active T3 in target tissues. The prohormone strategy provides smoother plasma levels than direct T3 administration, reflecting the long T4 half-life (approximately 7 days). Approved indications include primary, secondary, and tertiary hypothyroidism; thyroid cancer suppression therapy; goiter; and myxedema coma. Levothyroxine is the most prescribed drug in the United States by prescription count. Plasma half-life is approximately 7 days; absorption is impaired by food, calcium, iron, and proton pump inhibitors, requiring administration on an empty stomach with at least 4-hour spacing from interfering substances. Used as the canonical T4 reference compound.

Mechanism of action

Synthetic T4 prohormone; converted to active T3 by deiodinases in target tissues. Smoother plasma levels than direct T3 administration owing to long half-life.

Reported research dose ranges

Clinical 25 to 200 mcg in the published literature, on empty stomach. Rodent studies 5 to 50 mcg/kg.

References

Garber JR, et al. Clinical practice guidelines for hypothyroidism in adults. Thyroid 2012.
Hennessey JV. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine 2017.
Liwanpo L, Hershman JM. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab 2009.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-289

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Levothyroxine (T4)

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs